GRAIL Galleri for Unintended Weight Loss

Phase-Based Progress Estimates
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, OH
Unintended Weight Loss+2 More
GRAIL Galleri - DiagnosticTest
All Sexes
What conditions do you have?

Study Summary

Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. This study aims to test the potential synergistic effects of UWL detection and GRAIL usage to detect malignancy at an even earlier rate. UWL will be measured using weekly weight tracking.

Eligible Conditions

  • Unintended Weight Loss

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Unintended Weight Loss

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 3 years post-enrollment

Year 3
Malignant UWL Detection
Non-Malignant UWL Detection

Trial Safety

Safety Progress

1 of 3

Other trials for Unintended Weight Loss

Trial Design

1 Treatment Group

UWL and GRAIL Galleri Testing
1 of 1
Experimental Treatment

1000 Total Participants · 1 Treatment Group

Primary Treatment: GRAIL Galleri · No Placebo Group · N/A

UWL and GRAIL Galleri Testing
Experimental Group · 1 Intervention: GRAIL Galleri · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years post-enrollment
Closest Location: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center · Cleveland, OH
Photo of Cleveland 1Photo of Cleveland 2Photo of Cleveland 3
2022First Recorded Clinical Trial
1 TrialsResearching Unintended Weight Loss
18 CompletedClinical Trials

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
423 Previous Clinical Trials
28,647 Total Patients Enrolled
University Hospitals Seidman Cancer CenterOTHER
4 Previous Clinical Trials
97 Total Patients Enrolled
Jordan M Winter, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing to comply with all study procedures and be available for the duration of the study.
Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document.
Subjects must speak English to maximize chance of understanding the trial rational and study procedures.
You have access to a device that is compatible with the Aria Air smart scale.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.